Aspirin absorption rates and platelet inhibition times with 325-mg buffered aspirin tablets (chewed or swallowed intact) and with buffered aspirin solution

被引:58
作者
Feldman, M
Cryer, B
机构
[1] Dallas Vet Affairs Med Ctr 111, Med Serv, Dallas, TX 75216 USA
[2] Univ Texas, SW Med Sch, Dept Internal Med, Dallas, TX 75230 USA
关键词
D O I
10.1016/S0002-9149(99)00324-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Large clinical trials such as the second International Study of Infarct Survival routinely gave patients with myocardial infarction a chewed aspirin, yet there are no data to show whether chewing of aspirin is better, or worse, than swallowing a whole tablet. We performed a randomized, placebo-controlled study to determine whether chewing aspirin or administering it in solution accelerates its absorption and antiplatelet activity. On separate days, 12 fasting volunteers ingested 325 mg of buffered aspirin, either by chewing a tablet for 30 seconds before swallowing it with 4 ounces of water, swallowing a whole tablet with 4 ounces of water, or drinking 4 ounces of Alka Seltzer. Frequent blood samples were obtained for serum aspirin, salicylate, and thromboxane B-2 (TxB(2)) concentrations. With all formulations of aspirin, serum TxB(2) decreased 50% when the plasma aspirin concentration reached approximately 1,000 ng/ml, A 50% and 90% decrease in serum TxB(2) occurred more quickly after chewing a tablet than after a tablet was swallowed whole. For example, the t 50% for serum TxB(2) inhibition was 5.0 +/- 0.6 minutes with the chewed tablet versus 12.0 +/- 2.3 minutes when the tablet was swallowed (p = 0.01). A 50% decrease in serum TxB(2) occurred 7.6 +/- 1.2 minutes after Alka Seltzer solution (p = 0.04 vs chewing a tablet; p = 0.13 vs swallowing a whole tablet). Chewing an aspirin tablet is the most effective way of accelerating absorption of aspirin into the blood and shortening the time required for an anti-platelet effect, (C) 1999 by Excerpta Medica, Inc.
引用
收藏
页码:404 / 409
页数:6
相关论文
共 15 条
[1]  
ANDERSON HV, 1993, NEW ENGL J MED, V329, P703
[2]  
[Anonymous], 1988, LANCET, V2, P349
[3]  
Antman Elliott M., 1998, HARRISONS PRINCIPLES, P1352
[4]  
BERGER PB, 1998, ACUTE MYOCARDIAL INF, P1
[5]  
DROMGOOLE SH, 1994, APPL PHARMACOKINETIC, P32
[6]  
FITZGERALD GA, 1991, J PHARMACOL EXP THER, V259, P1043
[7]   ASPIRIN AS A THERAPEUTIC AGENT IN CARDIOVASCULAR-DISEASE [J].
FUSTER, V ;
DYKEN, ML ;
VOKONAS, PS ;
HENNEKENS, C .
CIRCULATION, 1993, 87 (02) :659-675
[8]   RAPIDITY AND DURATION OF PLATELET SUPPRESSION BY ENTERIC-COATED ASPIRIN IN HEALTHY-YOUNG MEN [J].
JIMENEZ, AH ;
STUBBS, ME ;
TOFLER, GH ;
WINTHER, K ;
WILLIAMS, GH ;
MULLER, JE .
AMERICAN JOURNAL OF CARDIOLOGY, 1992, 69 (03) :258-262
[9]   Simultaneous determination of acetylsalicylic acid and salicylic acid in human plasma by high-performance liquid chromatography [J].
Kees, F ;
Jehnich, D ;
Grobecker, H .
JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS, 1996, 677 (01) :172-177
[10]  
Lange RA, 1996, NEW ENGL J MED, V335, P1311